ArticleCureus2026
Incidence and Clinical Characteristics of Herpes Zoster in Patients With Spondyloarthritis Receiving Biologic Therapy: A 36-Month Multicenter Registry-Based Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHerpes zoster, caused by the reactivation of varicella-zoster virus, has been reported in patients with autoimmune inflammatory diseases receiving biologic therapies. However, data regarding its occurrence in patients with spondyloarthritis (SpA) remain limited. This study aimed to determine the incidence of herpes zoster and describe the clinical characteristics of affected patients with SpA receiving biologic therapy.
methodsA multicenter retrospective registry-based study was conducted over a 36-month period, including patients with SpA receiving biologic therapy and registered in the Moroccan Society of Rheumatology Biotherapy Registry (BRMSR). Clinical, laboratory data, including erythrocyte sedimentation rate and C-reactive protein, and therapeutic data were collected at baseline, at 36 months, and at the time of herpes zoster infection. A descriptive statistical analysis was performed.
resultsA total of 194 patients with SpA were included, with a mean age of 40.23 ± 13.68 years. The cohort included 123 males (63.4%) and 71 females (36.6%), with a mean disease duration of 11 ± 7 years. Most patients (98.5%) were treated with anti-tumor necrosis factor agents, with etanercept being the most commonly prescribed biologic therapy. The incidence of herpes zoster was 6.87 cases per 1,000 person-years (95% CI: 2.018-16.85). Four cases of herpes zoster were identified. These patients were all older than 55 years, had associated comorbidities, and had prolonged exposure to biologic therapy.
conclusionsThe incidence of herpes zoster in patients with SpA receiving biologic therapy was low. The four reported cases shared common clinical characteristics, including older age, the presence of comorbidities, and prolonged exposure to biologic therapy. Further studies with larger populations and longer follow-up are needed to better characterize herpes zoster occurrence in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.